Second Genome is a venture capital funded, life sciences research company based in South San Francisco.

[3] Second Genome was founded in 2010 by Corey Goodman, a venture capitalist and former Pfizer executive,[3] and Todd DeSantis, the company's vice president for informatics as of 2019.

[6] As of 2013, the company had entered into an ulcerative colitis research agreement with Janssen,[7] the financial arrangement and outcome of which remains to be determined.

[3] By 2016, the company had established a DNA sequencing service aimed at microbial samples, which provided revenue to supplement venture capital infusions.

[3] As of 2019, the company had secured a two-year SBIR grant in collaboration with Oregon State University, aimed at studying microbiome metabolites from people with nervous system disorders, in particular autism.